

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

DATE MAILED: 03/25/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/527,785	03/17/2000	Oleg N. Suslov	4350.001200	3947
7	590 03/25/2003			
Barbara S Kitchell AKERMAN SENTERFITT 222 LAKEVIEW AVE., SUITE 400 P.O. BOX 3188 WEST PALM BEACH,, FL 33402			EXAMINER	
			HAYES, ROBERT CLINTON	
			ART UNIT	PAPER NUMBER
WEST TALM	DEAOH,, 1 E 33402		1647	

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 09/527,785

Applicant(s)

Examiner

Robert C. Hayes, Ph.D.

Art Unit **1647**

Suslov et al



	ars on the cover sheet with the correspondence address			
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE				
	In no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
- If the period for reply specified above is less than thirty (30) days, a reply with	bly and will expire SIX (6) MONTHS from the mailing date of this communication.			
Status				
1) Responsive to communication(s) filed on <u>Dec 28</u>	, 2002			
2a) ☐ This action is FINAL . 2b) ☒ This a	action is non-final.			
3) Since this application is in condition for allowanc closed in accordance with the practice under Ex.	e except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims				
4) 🛛 Claim(s) <u>22-53</u>	is/are pending in the application.			
4a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) Claim(s)				
6) Claim(s)				
	is/are objected to.			
	are subject to restriction and/or election requirement.			
Application Papers				
9) \square The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/a	re a) \square accepted or b) \square objected to by the Examiner.			
	drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
If approved, corrected drawings are required in repl				
12) \square The oath or declaration is objected to by the Example 12.	niner.			
Priority under 35 U.S.C. §§ 119 and 120				
13) Acknowledgement is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some* c) ☐ None of:	·			
1. Certified copies of the priority documents ha				
	ve been received in Application No			
application from the international Bur	documents have been received in this National Stage eau (PCT Rule 17.2(a)).			
*See the attached detailed Office action for a list of t 14) Acknowledgement is made of a claim for domesti				
The state of the s				
 a) — The translation of the foreign language provision 15) — Acknowledgement is made of a claim for domesti 	all application has been received.			
Attachment(s)	c priority under 35 U.S.C. 33 120 and/or 121.			
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Cther:				

Application/Control Number: 09/527785 Page 2

Art Unit: 1647

DETAILED ACTION

Election/Restriction

1. Newly submitted claims 22-53 are directed to inventions that are independent or distinct from the invention originally claimed and examined, in which Applicants originally elected Group II (i.e., a collection of gene transcripts/RNA) in Paper No. 8 without traverse. Therefore, because different considerations and search parameters are used in a complete search of these structurally distinct cDNA libraries, which require different starting materials, different stages of differentiation with different genes being expressed, and because of the non-coextensiveness of the search and examination for each group would constitute an undue burden on the examiner to search and consider each of these separable groups, the following additional restriction requirement of elected Group II is now necessitated.

Note that failure to indicate by page and line number where proper basis exists for the elected invention will be held as being nonresponsive to this Office action, and may result in abandonment of this application.

Note further that it is suggested that improper claim dependencies be corrected (i.e., as it relates to unrelated and distinct inventions).

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - IIi. Claim 22 & 35, drawn to a microclonal cDNA library from a stem cell, classified in Class 435, subclass 320.1.

Art Unit: 1647

Note that claim 35 is directed toward single products, and not a method; and that no "collection" of the following individual cDNA libraries will be considered as being fully responsive to this restriction requirement, unless claims directed to gene transcripts from the complete whole brain at a specific stage of development are independently claimed.

- IIii. Claim 23 & 35, drawn to a microclonal cDNA library from a neural stem cell, classified in Class 435, subclass 320.1.
- IIiii. Claim 23 & 35, drawn to a microclonal cDNA library from a neuronal progenitor cell, classified in Class 435, subclass 320.1.
- IIiv. Claim 23 & 35, drawn to a microclonal cDNA library from a glial progenitor cell, classified in Class 435, subclass 320.1.
- IIv. Claim 24-25 & 35, drawn to a microclonal cDNA library from a glioma tumor cell, classified in Class 435, subclass 320.1.
- IIvi. Claim 26 & 35-36, drawn to a microclonal cDNA library from a hematopoietic cell, classified in Class 435, subclass 320.1.
- IIvii. Claims 27-29 & 32-36, drawn to a microclonal cDNA library from a human early type I neurosphere, classified in Class 435, subclass 320.1.
- IIviii. Claim 30 & 35-36, drawn to a microclonal cDNA library from a late type I neurosphere, classified in Class 435, subclass 320.1.
- Ilix. Claim 31 & 35-36, drawn to a microclonal cDNA library from a type II neurosphere, classified in Class 435, subclass 320.1.

Art Unit: 1647

- IIx. Claim 37, drawn to a microclonal cDNA library expressing *B*-actin, classified inClass 435, subclass 320.1.
- IIxi. Claim 37, drawn to microclonal cDNA library expressing *B*-2 microglobulin, classified in Class 435, subclass 320.1.
- IIxii. Claim 37, drawn to microclonal cDNA library expressing neuron-specific enolase, classified in Class 435, subclass 320.1.
- Ilxiii. Claims 37, drawn to microclonal cDNA library expressing neurofilament, classified in Class 435, subclass 320.1.
- IIxiv. Claim 37, drawn to microclonal cDNA library expressing MAP-2, classified in Class 435, subclass 320.1.
- IIxv. Claim 37, drawn to microclonal cDNA library expressing PAX-6, classified in Class 435, subclass 320.1.
- IIxvi. Claim 37, drawn to microclonal cDNA library expressing tenascin, classified in Class 435, subclass 320.1.
- IIxvii. Claim 37, drawn to microclonal cDNA library expressing nestin, classified in Class 435, subclass 320.1.
- IIxviii IIxxxiv. Claims 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 or 53, drawn to subtractive cDNA libraries in which each different library is individually restricted (i.e., including those from each of the

Application/Control Number: 09/527785 Page 5

Art Unit: 1647

different and distinct disease states listed in claim 53), classified in Class 435, subclass 320.1.

Note that claim 38 is directed toward single products, and not a method; and that no "collection" of the following individual subtractive cDNA libraries or "DNA fragments" will be considered as being fully responsive to this restriction requirement, unless claims directed to specific subtracted gene transcripts from the complete whole brain at specific stages of development are independently claimed.

3. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed. Additionally, in order to be fully responsive to this restriction requirement the claims will need to be amended to a separate cDNA library.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(I).

Application/Control Number: 09/527785

Art Unit: 1647

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Robert Hayes whose telephone number is (703) 305-3132. The examiner can normally be reached on Monday through Thursday, and alternate Fridays from 8:30 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Robert C. Hayes, Ph.D.

March 24, 2003

GARY KUNZ

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600